Abstract
The technique of accelerator mass spectrometry (AMS) is applicable to the analysis of a wide range of trace elemental isotopes. However, in the context of the pharmaceutical industry, it is invariably used to measure radiocarbon (14C). There are two broad modes of application: analysis of total 14C sometimes termed “direct AMS” and analysis of specific 14C-labelled analytes in a variety of matrices following some method of isolation. It is the latter application which is within the remit of the GBC team, and the team has made efforts to propose harmonized recommendations for the validation of AMS when used in a regulatory bioanalytical mode, i.e. the quantification of specific analyte(s) using liquid chromatography with off-line detection by AMS now known as “LC + AMS”. The GBC team has reached a position where they have agreed to many aspects, but also differ on some aspects of what constitutes a bioanalytical assay validation in support of clinical studies using this technology. The detail of most of this will be covered under separate publication(s), but for the purposes of this paper, we have outlined the points of consensus. The purpose of this article is not to provide a roadmap for validation of LC + AMS assays, but to highlight agreements amongst the industry representative experts and the practitioners, as well as identifying specific areas essential for establishing assay quality but where additional discussion is required to reach agreement.
Similar content being viewed by others
References
Higton D, Young G, Timmerman P, Abbott R, Knutsson M, Svensson LD. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry. Bioanalysis. 2012;4(22):2669–79. doi:10.4155/bio.12.242.
Keck BD, Ognibene T, Vogel JS. Analytical validation of accelerator mass spectrometry for pharmaceutical development. Bioanalysis. 2010;2(3):469–85. doi:10.4155/bio.10.14.
Timmerman P, Kall MA, Gordon B, Laakso S, Freisleben A, Hucker R. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum. Bioanalysis. 2010;2(7):1185–94. doi:10.4155/bio.10.90.
Vogel JS, Giacomo JA, Schulze-König TS, Keck BA, Lohstroh PN, Dueker SR. AMS best practices for accuracy and precision in bioanalytical 14C measurements. Bioanalysis. 2010;2(3):455–68. doi:10.4155/bio.10.13.
Xu XS, Dueker SR, Christopher LJ, Lohstroh PN, Keung CF, Cao KK, et al. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C] microdose absolute bioavailability study with accelerator MS. Bioanalysis. 2012;4(15):1855–70. doi:10.4155/bio.12.171.
Viswanathan CT. Bringing new technologies into the regulatory space. Bioanalysis. 2012;4:2763–4. doi:10.4155/bio.12.266.
Lappin G, Seymour M, Young G, Higton D, Hill HM. AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. Bioanalysis. 2011;3(4):393–405. doi:10.4155/bio.11.5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editors: Binodh DeSilva and Philip Timmerman
Rights and permissions
About this article
Cite this article
Young, G.C., Seymour, M., Dueker, S.R. et al. New Frontiers—Accelerator Mass Spectrometry (AMS): Recommendation for Best Practices and Harmonization from Global Bioanalysis Consortium Harmonization Team. AAPS J 16, 357–359 (2014). https://doi.org/10.1208/s12248-014-9568-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-014-9568-9